$PFE Recent News Apple looks ready to head higher 3:48

New Post Public Reply Private Reply Replies (0) Message Board

Mar 24, 2014 at 9:48 AM

$PFE Recent News

Apple looks ready to head higher 3:48 p.m. March 17, 2014 - blogs.marketwatch.com
Apple as the Comeback Kid 1:13 p.m. March 13, 2014 - Mark Hulbert
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Pfizer loses ruling on Celebrex patent dispute 2:46 p.m. March 12, 2014 - Russ Britt
Trading resumes on Pfizer shares 2:37 p.m. March 12, 2014 - Russ Britt
Ruling invalidates Pfizer's Celebrex patent 2:36 p.m. March 12, 2014 - Russ Britt
Pfizer obtained reissue patent on Celebrex in 2013 2:35 p.m. March 12, 2014 - Russ Britt
Pfizer plans to appeal ruling on Celebrex judgment 2:31 p.m. March 12, 2014 - Russ Britt
Pfizer loses ruling on Celebrex patent dispute 2:30 p.m. March 12, 2014 - Russ Britt
Pfizer halted 2:15 p.m. March 12, 2014 - Steve Goldstein
S&P 500 extends the break to ‘clear skies’ territory 10:46 a.m. March 6, 2014 - Michael Ashbaugh
Newscast: Stocks take a spill to start the week 4:26 p.m. March 3, 2014 - MarketWatch
Pfizer aims to sell over-the-counter version of Lipitor 8:13 a.m. March 3, 2014 - Peter Loftus
Newscast: Pfizer moves to make Lipitor OTC 7:39 a.m. March 3, 2014 - MarketWatch
Best stocks for legalized marijuana 1:37 p.m. Feb. 27, 2014 - blogs.marketwatch.com
Pfizer pneumonia vaccine study meets objectives 7:45 a.m. Feb. 24, 2014 - MarketWatch.com
You'd have to be a dope to buy marijuana stocks 1:36 p.m. Feb. 13, 2014 - blogs.marketwatch.com
Australia regulator takes action against Pfizer 11:03 p.m. Feb. 12, 2014 - MarketWatch.com
Pfizer, GE, Boeing lead early Dow advancers 9:34 a.m. Feb. 11, 2014 - William L. Watts

A Dividend Investing History Lesson - Pfizer And FirstEnergy Corporation 5:28 p.m. March 23, 2014 - Seeking Alpha
Proposed Law Would Require More Drug-Trial Transparency 5:01 p.m. March 21, 2014 - The Wall Street Journal Interactive Edition
The 5 Stocks That Sank Markets on Friday 3:28 p.m. March 21, 2014 - 247WallSt.com
March Madness: Final Four Investing Bracket 2014 6:36 p.m. March 20, 2014 - Seeking Alpha
Recent Trials Could Help Pfizer Solidify Its Dominance In Pneumococcal Vaccine Market 4:11 p.m. March 20, 2014 - Seeking Alpha
Glaxo's Stock May Suffer Drowsiness 2:22 p.m. March 20, 2014 - The Wall Street Journal Interactive Edition
Pfizer meningococcal disease vaccine gets breakthrough designation 8:56 a.m. March 20, 2014 - Seeking Alpha
Should You Take a Chance With Novartis? 3:52 p.m. March 19, 2014 - Wall St. Cheat Sheet
Why Pfizer's Debt Levels Should Be Of Little Concern 12:10 p.m. March 19, 2014 - Seeking Alpha
Insider Trading Alert - PFE, WOOF And BOBE Traded By Insiders 11:15 a.m. March 19, 2014 - TheStreet.com
Stock Market News for March 19, 2014 - Market News 10:06 a.m. March 19, 2014 - Zacks.com
Promising Biotechs Target New Ways To Kill Bad Bugs: Venture Capitalist Dennis Purcell 7:34 a.m. March 19, 2014 - Seeking Alpha
Milestone Payment for Ligand Pharma - Analyst Blog 5:30 p.m. March 18, 2014 - Zacks.com
Pfizer Inc (PFE): Today's Featured Health Care Winner 5:00 p.m. March 18, 2014 - TheStreet.com
Bristol-Myers, Five Prime Join Forces, Shares up - Analyst Blog 12:00 p.m. March 18, 2014 - Zacks.com
Pfizer sues Indian company over Viagra 4:59 a.m. March 18, 2014 - Seeking Alpha
MannKind Corporation: Will It Make It to the Promised Land? 5:46 p.m. March 17, 2014 - GuruFocus.com
Update on Bayer's Adempas - Analyst Blog 2:23 p.m. March 17, 2014 - Zacks.com
Nestlé's China Business Head Departs 12:41 p.m. March 17, 2014 - The Wall Street Journal Interactive Edition
Amgen's PCSK9 Scores Against Genetic High Cholesterol 10:36 a.m. March 17, 2014 - Investors Business Daily

Pfizer Announces Detailed Results of OPT Compare Phase 3 Study of Tofacitinib 5 mg and 10 mg Twice Daily Compared to High-Dose ENBREL® in Adults with Moderate-to-Severe Chronic Plaque Psoriasis 11:45 a.m. March 22, 2014 - BusinessWire - BZX
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA 8:00 a.m. March 21, 2014 - PR Newswire - PRF
Pfizer’s Investigational Vaccine Candidate Bivalent rLP2086 Receives U.S. Food and Drug Administration Breakthrough Therapy Designation for Potential Prevention of Meningococcal B Disease 8:31 a.m. March 20, 2014 - BusinessWire - BZX
Healthcare Companies Report FDA Approvals, Comprehensive Analysis, Schedules, and Stock Movements - Analyst Notes on Pfizer, Johnson & Johnson, Biogen, Express Scripts, and Forest Laboratories 8:00 a.m. March 20, 2014 - PR Newswire - PRF
Avanir Pharmaceuticals Announces Appointment of Mark Corrigan to Board of Directors 4:00 p.m. March 19, 2014 - PR Newswire - PRF
ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence 9:45 a.m. March 19, 2014 - PR Newswire - PRF
Insider Trading Research - Alerts for Microsoft, Oracle, Pfizer, Plug Power, Sirius XM, and Bank of America 8:55 a.m. March 19, 2014 - PR Newswire - PRF
Portola Pharmaceuticals Initiates Phase 3 Study of Andexanet Alfa, Potential First-in-Class Factor Xa Inhibitor Reversal Agent, Under Accelerated Approval Pathway 8:15 a.m. March 19, 2014 - GlobeNewswire
Pfizer Launches 2013 Integrated Annual Review 10:00 a.m. March 18, 2014 - BusinessWire - BZX
Healthcare Companies Receive Approvals, Recognitions, Agreements, and Announce Senior Level Appointments- Analyst Notes on Pfizer, Boston Scientific, WellPoint, Aetna, and Humana 8:00 a.m. March 18, 2014 - PR Newswire - PRF
U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery 1:00 p.m. March 14, 2014 - BusinessWire - BZX
Insider Trading Alert - Research Report on Facebook, Intel, Yahoo, Plug Power, FuelCell Energy, and Pfizer 8:55 a.m. March 14, 2014 - PR Newswire - PRF
Pfizer Will Appeal Court Decision Regarding Celebrex Reissue Patent 2:28 p.m. March 12, 2014 - BusinessWire - BZX
Pfizer Announces Webcast Of April 6 Conference Call With Securities Analysts To Review Palbociclib Phase 2 Final Results Following Presentation At AACR Annual Meeting 2014 10:01 a.m. March 12, 2014 - BusinessWire - BZX
Pfizer Presents Detailed Results From Landmark Community-Acquired Pneumonia Immunization Trial In Adults (CAPiTA)Evaluating Efficacy Of Prevenar 13* 6:37 a.m. March 12, 2014 - BusinessWire - BZX
American DG Energy and Pepco Well Positioned as Coke eBay and More Employ Cogeneration Systems 10:08 a.m. March 11, 2014 - ACCESSWIRE
Pfizer Initiates Nationwide Voluntary Recall of Two Lots of Pfizer’s Effexor XR® 150 Mg Extended-Release Capsules and One Lot of Greenstone’s Venlafaxine HCl 150 Mg Extended-Release Capsules Due to the Possible Presence of Tikosyn® Capsules 5:15 p.m. March 6, 2014 - BusinessWire - BZX
Morning Briefing - 52-Weeks High Breakers: Wells Fargo, Corning, Delta Air Lines and Pfizer 12:16 p.m. March 6, 2014 - PR Newswire - PRF
Critical Alerts For Autodesk, Pfizer, Arrowhead Research, Discover Financial, and Vodafone Released By InvestorsObserver 9:31 a.m. March 6, 2014 - PR Newswire - PRF
Price Movements, Clinical Trial Results, and Solid Financial Reports - Analyst Notes on Pfizer, Dendreon, DepoMed, Globus Medical, and Array 1:13 p.m. March 5, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Damp or Dry: The Battle for Healthy Air in Colorado

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

D-Wave Faces Legal Questions After CFO Exit and Losses

Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...

Pizza: The Unlikely Symbol of Universal Togetherness

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Ajman Spotlights Tourism at Arabian Travel Market 2026

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Larry Ellison's Moves Signal Confidence in Oracle's Future

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

U.S. Green Beret's Mission: Clearing Landmines in Ukraine

The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

PwC US and India Unite for Global Consultancy Powerhouse

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...